Novartis AG Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated January 25, 2012, reports the full-year 2011 and fourth-quarter 2011 financial results for Novartis AG, a global diversified healthcare company headquartered in Basel, Switzerland. The reporting period covers the fiscal year ended December 31, 2011. The company operates across six divisions: Pharmaceuticals, Alcon (Eye Care), Sandoz (Generics), Vaccines and Diagnostics, and Consumer Health (OTC and Animal Health).
Key Financial Metrics
| Metric | Q4 2011 | Q4 2010 | FY 2011 | FY 2010 |
|---|---|---|---|---|
| Net Sales (USD bn) | 14.8 | 14.2 | 58.6 | 50.6 |
| Operating Income (USD bn) | 1.3 | 2.5 | 11.0 | 11.5 |
| Net Income (USD bn) | 1.2 | 2.3 | 9.2 | 10.0 |
| EPS (USD) | 0.49 | 0.95 | 3.83 | 4.28 |
| Free Cash Flow (USD bn) | 3.9 | 4.2 | 12.5 | 12.3 |
| Net Debt (USD bn) | 15.2 (as of Dec 31, 2011) |
Core Performance (Constant Currency): Core operating income grew 17% in Q4 and 16% for the full year. Core EPS increased 13% in Q4 and 11% for the full year. Core operating income margin for the full year was 27.2%.
Material Changes vs. Prior Period
- Revenue Growth: Full-year net sales rose 16% (12% in constant currency), driven by recently launched products which contributed 25% of total sales. Pharmaceuticals sales grew 7% (4% cc), while Alcon sales grew 10% (7% cc) on a pro forma basis.
- Profitability Decline: Reported operating income fell 47% in Q4 and 5% for the full year. This was primarily due to net exceptional charges of USD 1.5 billion in Q4 and USD 1.9 billion for the full year.
- Exceptional Items: Major charges included USD 903 million related to the Tekturna/Rasilez (aliskiren) portfolio following the halt of the ALTITUDE trial, USD 348 million for discontinued development programs, and USD 115 million for a temporary suspension of production at a US Consumer Health site.
- Currency Impact: The strengthening of the US dollar negatively impacted reported sales and margins, though constant currency figures showed stronger underlying performance.
Guidance, Outlook, and Risks
- 2012 Outlook: Novartis expects 2012 sales to be in line with 2011 levels. Core operating income margin in constant currencies is expected to be slightly below 2011 levels.
- Key Risks & Contingencies:
- Tekturna/Rasilez: The ALTITUDE trial was halted due to higher adverse events in patients with diabetes taking the drug in combination with ACE inhibitors or ARBs. Sales are expected to be less than half of 2011 levels in 2012.
- Gilenya: Regulatory reviews by the FDA and EMA are ongoing regarding a patient death following the first dose. New interim recommendations for ECG monitoring during the first dose have been issued in the EU.
- Patent Expirations: The company anticipates revenue loss from Diovan patent expiry and generic competition.
- Manufacturing: A temporary suspension of production at the Lincoln, Nebraska site impacted Consumer Health sales and required a USD 115 million charge.
- Dividend: The Board proposed a dividend of CHF 2.25 per share for 2011, representing the 15th consecutive increase.
Investor Verification Checklist
- Verify the magnitude of the USD 903 million charge related to Tekturna/Rasilez and the specific impact on future cardiovascular franchise revenue.
- Confirm the status of the FDA and EMA reviews for Gilenya and the potential impact of new safety monitoring requirements on market uptake.
- Assess the timeline for the resumption of full production at the Lincoln, Nebraska Consumer Health facility and the associated cost implications.
- Review the integration progress of Alcon and the realization of projected cost synergies (USD 75 million realized in 2011).
- Monitor the performance of recently launched products (e.g., Gilenya, Tasigna, Lucentis) which now account for 25% of group sales, as they are critical to offsetting patent expirations.